GLP-1 Receptor Agonist Market On the other hand, the Canadian government is initiating plans, including Canada's Diabetes 360, aimed at minimizing diabetes prevalence, with funding allocated to novel treatment choices like GLP-1 receptor agonists
For someone who consistently feels out of control around food and ignores their bodys satiety cues, GLP-1s could help diminish the reward-like quality of a binge while making their fullness louder and harder to ignore
And recent research published in JAMA Network Open suggests older adults are more likely than their younger peers to discontinue these popular medications
[,] GLP-1/GIP co-agonists, GIP/GLP-1/Gcg triple agonist, and GIP-antagonist GIP/GLP-1 co-agonist is the drug of choice for diabetes, as it shows efficacy in decreasing the elevated levels of blood glucose, increasing weight loss with a lower risk of hypoglycemic shock, and also having the CVS benefits
Whilst transdermal patch delivery systems are being explored in research, it is crucial to understand that no GLP-1 patches are currently licensed or approved for use in the UK
Use of GLP-1 medications Source: Montero, et al KFF, November 14, 2025 KFF published survey data showing that one in 12 American adults report that they are currently taking GLP-1 medications
